Sulfasalazine: I. An Historical Perspective

The American Journal of Gastroenterology

Volumn 83, Issue 5, 1988, Pages 487-496

  Bachrach, William H ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

SALAZOSULFAPYRIDINE;

DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOXICITY; HISTORY; HUMAN; PHARMACOKINETICS; REVIEW; ULCERATIVE COLITIS;

ANIMAL; ARTHRITIS, RHEUMATOID; COLITIS, ULCERATIVE; CROHN DISEASE; HISTORY OF MEDICINE, 20TH CENT.; HUMAN; SULFASALAZINE;

EID: 0023907372     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.1988.tb02402.x     Document Type: Article

References (137)

1. Keratoconjunctivitis sicca caused by sulfadiazine
2. Drug treatment of ulcerative colitis
3. Water and electrolyte transfer by colonic mucosa studied in vitro
4. Crohn's disease: A clinical study of 75 patients
5. The management of patients with ulcerative colitis
6. Sulphasalazine and salicylazosulphadimidine in ulcerative colitis
7. Assay of salazopyrin
8. Drug‐induced blood dyscrasias. III. Hemolytic anemia
9. Pancreatitis as an adverse reaction to salicylazosulfapyridine
10. The occurrence of Heinz bodies during azulfidine treatment of ulcerative colitis
11. Metabolic studies on azulfidine, azudimidine and one analogue
12. Effects on prostaglandin biosynthesis of drugs affecting gastrointestinal function
13. Erythema multiforme, drugs, and ulcerative colitis
14. La salazopyrina nel trattamento della colite ulcerosa criptogenetica
15. Risultati delia terapia della colite ulcerosa con salicilazosulfapiridina
16. Agranulocytosis associated with sulfasalazine (salicylazosulfapyridine) therapy
17. Ulcerative colitis and erythrocyte G6PD deficiency. Salicylazosulfapyridine–provoked hemolysis
18. Adverse reactions to salicylazosulfapyridine (azulfidine) in the treatment of ulcerative colitis
19. Faecal flora of patients with ulcerative colitis during treatment with salicylazosulphapyridine
20. Drug agranulocytosis. A case study
21. Salicylazosulfapyridine in clinical practice
22. Effect of iron and calcium on salicylazosulphapyridine metabolism
23. Salazopydne metabolism in ulcerative colitis
24. The metabolism of salicylazosulphapyridine in ulcerative colitis. I. The relation ship between metabolites and the response to treatment in inpatients
25. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype
26. The role of the colon in the metabolism of salicylazosulphapyridine
27. Fibrosing alveolitis and treatment with sulphasalazine
28. Controlled trial on sulphasalazine in the treatment of ulcerative colitis
29. A controlled therapeutic trial of long‐term maintenance treatment of ulcerative colitis with sulphazalazine (salazopyrin)
30. Early histological changes in ulcerative colitis. A light and electron microscopic study
31. Salazopyrin (azulfidine) treatment of scleroderma
32. Sulphasalazine–induced lung disease
33. Neuropathy in Tangier disease. Alpha‐lipoprotein deficiency manifesting as familial recurrent neuropathy and intestinal lipid storage
34. Làssociazione salicilico‐sulfamidica in terapia
35. Studies of the bone marrow in immunological granulocytopenia following administration of salicylazosulfapyridine
36. Migratory pneumonia with eosinophilia associated with sulfonamide administration
37. Non‐oxidative hemolysis due to salicylazosulfapyridine: Evidence for an immune mechanism
38. Impaired folic acid absorption in inflammatory bowel disease: Effects of salicylazosulfapyridine (azulfidine)
39. Blood concentration, acetylation and urinary excretion of sulfapyridine and sulfathiazole after various sulfapyridine and sulfathiazole derivatives administered by different routes
40. Hemolytic anemia as adverse reaction to salicylazosulfapyridine
41. Hemolytic anemia secondary to salicylazosulfapyridine therapy
42. Therapeutic implications of the intestinal microflora
43. Salicylazosulfapyridine in clinical practice
44. Nature of the tissue reaction in ulcerative colitis
45. Studies of intestinal microflora. V. Fecal microbial ecology in ulcerative colitis and regional enteritis: Relationship to severity of disease and chemotherapy
46. Salazopyrine bij ed behandeling van diarrheen tengevolge van dyspeptische stoomissen
47. 14‐5‐aminosalicyclic acid
48. 35‐sulfapyridine
49. Regional enterocolitis (Crohn's disease). Clinical signs
50. Determination of free and acetylated 5–amino‐salicyclic acid in serum and urine after administration of salicylazosulphapyridine
51. Determination of sulphapyridine and its metabolites in biological materials after administration of salicylazosulphapyridine
52. The effect of salazopyrin on water and electrolyte transport in the human colon measured in vivo and in vitro
53. Chronic ulcerative colitis III. Treatment
54. Adverse reaction to salazopyrine
55. Pulmonary vasculitis: An uncommon complication of ulcerative colitis. Report of a case
56. Azulfidine agranulocytosis with bone marrow megakaryocytosis, histiocytosis and plasmacytosis
57. Sulphasalazine induced lung disease
58. Hamolyse, Heinz‐Korper und Methamoglobin bildung unter Azulfidine‐Therapie
59. Hemolytic effect of commonly used drugs on erythrocytes deficient in glucose‐6‐phosphate dehydrogenase
60. Zur Problematik der colitis ulcerosa
61. Pancytopenia during salazopyrin treatment. Ann 91
62. Ulcerative colitis in children
63. Effects of sulphasalazine (salazopyrin) on faecal flora in patients with inflammatory bowel disease
64. An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as out‐patient treatment for ulcerative colitis
65. A new concept of the 95
66. Pharmacokinetics and azo‐link cleavage of salazopyrine in man
67. Die behandlung der colitis ulcerosa
68. Mild ulcerative colitis
69. Agranulocytose under behandling med salicylazo‐sulfapyridin (salazopyrin)
70. Ulcerative colitis in children. II. Medical and surgical therapy
71. Methamoglobinbildung unter azulfidinetherapie
72. Untersuchungen zum mechanismus der hamiglobinbildung durch salicylazosulfapyridin (azulfidine)
73. Controlled trial of sulphasalazine in maintenance therapy for ulcerative colitis
74. A critical analysis of the use of salicylazosulfapyridine in chronic ulcerative colitis
75. Results of treatment of ulcerative colitis with salicylazosulfapyridine
76. Response of ulcerative colitis to therapy with salicylazosulfapyridine
77. Investigations on the absorption of azulfidine
78. Present‐day concepts of the treatment of ulcerative colitis
79. Et tilfelle av agranulocytose etter behandling med salazopyrin
80. Role of intestinal bacteria in the metabolism of salicylazosulfapyridine
81. Distribution studies of salicyla‐zosulfapyddine and its metabolites
82. Quantitative TLC of salicylazosulfapyridine
83. Systemic granulomatous reaction to salicylazosulfapyridine (azulfidine) in a patient with Crohn's disease
84. Tratamiente medico especifico de la colitis ulcerosa
85. The prophylactic effect of salazosulphapyridine in ulcerative colitis during long‐term treatment. A double‐blind trial on patients asymptomatic for one year
86. Toxic depression of the myeloid elements following therapy with the sulfonamides; report of 8 cases
87. Agranulocytosis due to administration of salicylazosulfapyridine (azulfidine)
88. A fatal case of azulfidine‐induced agranulocytosis
89. The treatment of ulcerative colitis. Analysis of 82 cases
90. Determination of salicylazosulfapyridine in biological materials
91. Isolierte aplastische Anamie (akute benigne Erythroblastopenie “Gasser”) bei colitis ulcerosa
92. The effect of salicylazosulfapyridine (azulfidine) on pustular acne vulgaris and certain other dermatoses
93. Simplified method for determining acetylator phenotype
94. Absorption, metabolism, and excretion of salicylazosulfapyridine in man
95. The polymorphic acetylation of sulphapyridine in man
96. Acetylator phenotype and adverse effects of sulfasalazine in healthy subjects
97. Azo reduction of salicyl‐azo‐sulphapyridine in germ‐free and conventional rats
98. Metabolism of salicylazosulfapyridine in healthy subjects and in patients with ulcerative colitis. Effects of colectomy and of phenobarbital
99. Uber die rektale Wirkung von Salazopyrin bei colitis ulcerosa im doppelten Blindversuch
100. Ulcerative colitis: What do such patients know and think about their medications
101. Heinz‐body anemia due to salicylazosulphapyridine
102. The spectrum of cholestatic hepatic disease
103. Improved method for salicylazosulfapyridine analysis and partial characterization of impurities in commercial salicylazosulfapyridine
104. Toxic epidermal necrolysis (Lyell's syndrome). A report on four cases with three deaths
105. Ett nytt sulfonamidpreparat. Forelopande meddelande
106. Erfarenheter med salazopyrin
107. Behandlung der ulzerosen Kolitis mit Salazopyrin
108. Verkan och biverkan av salazopyrin
109. Salazopyrin, a new sulfanilamide preparation: a. therapeutic results in rheumatic polyarthritis; b. therapeutic results in ulcerative colitis; c. toxic manifestations in treatment with sulfanilamide preparations
110. Modem kemoterapi vid tarm: Och ledaffektioner
111. The treatment of 124 cases of ulcerative colitis with salazopyrine and attempts of desensibilization in cases of hypersensitiveness to sulfa
112. Ueber die therapeutische Wirkung der Azoverbindungen der Salicylsaure mit Sulfapraparaten
113. The pathogenesis and treatment of ulcerative colitis
114. The treatment of ulcerative colitis
115. The treatment of ulcerative colitis
116. Treatment of rheumatoid arthritis with salicylazosulfapyridine
117. Ulcerative colitis: changes in the intestinal walls and therapeutic considerations
118. The importance of autoradiographic methods for studies of the tissue affinity of different drugs
119. Treatment of ulcerative colitis with salazopyrin
120. Cyanosen vid behandling med sulfonamidpreparat
121. Fortsatta undersokningar over biverkningar vid behandling med sulfonamid‐preparat samt en kort redogorelse for nya terapeutiska forsok
122. Cyanosis in treatment with sulfonamide compounds
123. Sonderdelas salazopyrin snabbt i organismen
124. Continued autoradiographic studies on drug affinity for the intestinal wall and other tissues
125. Agranulocytosis associated with sulphasalazine (salazopyrin) therapy
126. Respiratory disease due to sulphasalazine
127. Medical management of ulcerative colitis
128. The management of ulcerative colitis
129. Comparison of corticosteroid and sulphasaline therapy in ulcerative colitis
130. The drug therapy of ulcerative colitis and of Crohn's disease
131. Neurotoxicity associated with a reaction to sulphasalazine
132. Medical management of ulcerative colitis
133. Effects of sulphasalazine (salazopyrin) on faecal flora in patients with inflammatory bowel disease
134. Unusual cause of yellow skin
135. Treatment of ulcerative colitis